Carcinosarcoma - 15 Studies Found

Active, not recruiting : Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
:
  • Endometrial Adenocarcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Breast Carcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • End
    : 2016-08-17
    :
    • Drug: Metformin Hydrochloride

Completed : APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
: Fallopian Tube Carcinosarcoma
: 2025-08-01
: Given IV
Completed : A Study of FRaDCs for Ovarian Cancer
: Fallopian Tube Carcinosarcoma
: 2025-08-01
: Undergo biopsy
Completed : A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
: Endometrial Carcinosarcoma
: 2025-08-01
: Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
<<< Previous